Helixmith Announces Acceptance of Abstracts for 2020 Annual NEALS Meeting
Helixmith, a gene therapy company, announced today that three abstracts have been accepted for poster presentations at the virtual 2020 Annual NEALS Meeting to be held September 30th and October 1st.
SAN DIEGO, Sept. 30, 2020 /PRNewswire-PRWeb/ -- Helixmith, a gene therapy company, announced today that three abstracts have been accepted for poster presentations at the virtual 2020 Annual NEALS Meeting to be held September 30th and October 1st.
Details of the poster presentations are as follows:
Title: Introducing a Drug Development Platform for ALS, DART (Defeating ALS through Restorative Therapeutics)
Poster Number: 89
Presenter: Dr. Sunyoung Kim, CEO, Helixmith
Title: Gene Therapy for ALS: A Phase 1/2 Study of VM202 (Engensis®), a Plasmid DNA Encoding Human Hepatocytes Growth Factor and Plan for Phase 2
Poster Number: 48
Presenter: Dr. John A. Kessler, Professor of Neurology, Pharmacology, and Stem Cell Biology, Northwestern School of Medicine
Title: Intrathecal delivery of recombinant AAV1 encoding human hepatocyte growth factor (HGF) improved motor functions and protects neuromuscular system in two mouse models, nerve crush and SOD1-G93A transgenic
Poster Number: 07
Presenter: Dr. Boram Nho, Research Scientist, Helixmith
Dr. Kim, Dr. Kessler, and Dr. Nho will be available to answer questions on our posters during the live Virtual Poster Session on September 30th from 5:30 pm – 6:30 pm EST. Please visit https://www.neals.org/for-als-researchers/annual-neals-meeting/ for full information including registration.
About Helixmith
Helixmith is a gene therapy company headquartered in Seoul, Korea, developing new and innovative biopharmaceuticals to tackle previously untreated diseases, and is listed on KOSDAQ. The company has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an AAV vector program targeting neuromuscular diseases. Engensis (VM202), a more advanced pipeline candidate, is a plasmid DNA therapy being studied for diabetic peripheral neuropathy, diabetic foot ulcers, claudication, amyotrophic lateral sclerosis (Phase 2 beginning in late 2020), coronary artery disease, and Charcot-Marie-Tooth disease.
Helixmith clinical development and manufacturing activities are based in San Diego, California, where the company co-owns a cGMP-ready DNA production facility, Genopis, Inc., an affiliated CDMO also in San Diego. Genopis serves both Helixmith and external customers in need of plasmid DNA for medical purposes.
SOURCE Helixmith Co., Ltd
Share this article